key: cord-0995811-g1pa2l05 authors: Couto, Márcia R.; Rodrigues, Joana L.; Rodrigues, Lígia R. title: Heterologous production of chondroitin date: 2022-02-10 journal: Biotechnol Rep (Amst) DOI: 10.1016/j.btre.2022.e00710 sha: fec94568a88df28acf2f3273ec856a746a4ef1eb doc_id: 995811 cord_uid: g1pa2l05 Chondroitin sulfate (CS) is a glycosaminoglycan with a broad range of applications being a popular dietary supplement for osteoarthritis. Usually, CS is extracted from animal sources. However, the known risks of animal products use have been driving the search for alternative methods and sources to obtain this compound. Several pathogenic bacteria naturally produce chondroitin-like polysaccharides through well-known pathways and, therefore, have been the basis for numerous studies that aim to produce chondroitin using non-pathogenic hosts. However, the yields obtained are not enough to meet the high demand for this glycosaminoglycan. Metabolic engineering strategies have been used to construct improved heterologous hosts. The identification of metabolic bottlenecks and regulation points, and the screening for efficient enzymes are key points for constructing microbial cell factories with improved chondroitin yields to achieve industrial CS production. The recent advances on enzymatic and microbial strategies to produce non-animal chondroitin are herein reviewed. Challenges and prospects for future research are also discussed. Glycosaminoglycans (GAGs) are naturally occurring heteropolysaccharides with polyanionic character. They consist of repeating disaccharide units composed of an N-acetylated or N-sulfated hexosamine (glucosamine, GlcN or galactosamine, GalN) and either a uronic acid (glucuronic acid, GlcA or iduronic acid, IdoA) or galactose (Gal). There are four main types of GAGs that vary in their monomeric composition, glycosidic bonds and sulfation pattern: hyaluronic acid (hyaluronate, hyaluronan, HA); keratan sulfate (KS); chondroitin sulfate/dermatan sulfate (CS/DS, stereoisomers); and heparin/heparan sulfate (HP/HS) [1] . The chemical structures of the repeating disaccharide units of different GAGs are represented in Fig. 1 . While HA lacks sulfate groups, the remaining GAGs can contain sulfates at various positions. DS is distinguished from CS by the presence of IdoA. HS is the only glycosaminoglycan that contains a N-sulfated hexosamine and differs from HP by possessing less sulfated units and less content of epimerized entities into IdoA. Heparosan is the non-sulfated precursor to HS and HP. Keratan sulfate lacks uronic acids and instead contains sulfated Gal residues. In animals, GAGs usually exist as long chains covalently bound to a protein core, as part of proteoglycans [2] . Depending on their molecular structure, GAGs have a wide distribution through tissues and perform different physiologic functions including in structural support, cell recognition and signaling, matrix organization, inflammation, cell division, and tissue repair and development [3, 4] , being particularly common in connective tissues such as the skin, bone, cartilage, and the intervertebral discs [5] . Some bacterial pathogens produce GAG-like polysaccharides as part of their capsule composition, which contribute to their pathogenicity [6] [7] [8] . The wide applications of GAGs in medicine, veterinary, cosmetics, and pharmaceutics have been extensively reviewed [5, 9, 10] . The most famous GAG clinical application is the use of HP as an anticoagulant drug. Furthermore, GAGs also exist as nutraceuticals in human and veterinary supplements, serve as cosmetic or pharmaceutical ingredients, or act as materials for several biomedical applications such as tissue engineering. The industrial production of GAGs can be classified in 4 types: (i) extraction from animal sources; (ii) chemical synthesis; (iii) enzymatic or chemoenzymatic production or (iv) microbial or animal cells fermentation. Regarding microbial fermentation, the industrial production of HA is currently the most well established due to its simple structure that does not undergo sulfation or epimerization contrarily to the other GAGs. However, sulfated GAGs such as CS, HS, HP and KS are usually chemically extracted from animal sources, through a laborious process that requires a large amount of environmentally hazardous thus increase their pathogenicity [6] . Commercial CS is usually provided as a mixture of CS-A and CS-C, the most common CS in animal cartilage [67] , which is obtained through chemical extraction and purification from animal cartilaginous tissues, mainly from bovine, porcine, shark and chicken. The structural composition, molecular weight and yields of CS obtained from extraction vary not only with the extraction method but also with the animal and tissue used. Some of the reported CS yields include: extraction from shark fin resulted in 150.5 mg/g dry cartilage [68] ; from blue shark head wastes 120.8 mg/g dry cartilage was obtained; crocodile hyoid, rib, sternum, trachea cartilages generated 91 -274 mg/g of dry cartilage [68] ; 75 mg/g of dry weight has been achieved by extraction from ray [68] ; buffalo nasal, joint and tracheal cartilages generated 60 to 62 mg/g of dry cartilage [69] ; using chicken keel, 24.8 mg/g of wet cartilage were obtained [70] ; from different sea cucumbers, fucosylated CS (fCS) yields varied from 63 to 110 mg/g weight [54] ; and from fish by-products, yields from 19 to 137 mg/g dry cartilage have been achieved [71] . In addition to the relatively low yields, the shortage of such materials and the concerns on intraspecies contamination led to studies on artificial synthesis of the chondroitin backbone, either using chemical synthesis, enzymatic, chemo-enzymatic and microbial fermentation strategies. Given the growing potential applications of CS, and the rising prevalence of osteoarthritis due to the increase in average life expectancy among the population, a boost in its demand and market volume has been registered. The global CS market size was valued as USD 1.17 billion in 2020 and is expected to grow at a compound annual growth rate (CAGR) of 3.0% from 2020 to 2028 [72] . In 2018, China was the biggest producer accounting for 83.7% of CS produced globally [73] . Depending on their application, different systems have been implemented for the administration of chondroitin and its derivatives, including oral administration as food additives, in pharmaceutical preparations, nutraceuticals or veterinary supplements [74, 75, 76, 77] ; incorporation in intra-articular or intravenous injectables [78] ; integration in skin dermatology/cosmeceutical and ophthalmic products [79, 80, 81] ; as part of medical devices [82, 83, 84, 85] ; or as biomaterials for regenerative medicine [9, 86] . The current main application of CS is as nutraceutical to treat osteoarthritis symptoms and retard cartilage degradation [77, 87] . These supplements have been widely prescribed for humans and animals and are usually formulated with glucosamine. Although the results on the efficacy of chondroitin or its combination with glucosamine in joint repair and pain relief compared with placebo have not always been concurrent [88, 89, 90, 91] , CS and glucosamine have been recommended in guidelines, prescribed by general practitioners and rheumatologists as over-the-counter drugs and suggested by the European League Against Rheumatism (EULAR) to patients with knee and hand osteoarthritis [92] . The variable efficacy of CS is in part attributed to its highly variable composition. Since they are over-the-counter supplements, they are not tightly controlled and can differ in the biological source, purification method and ingredient amount and type, thus [93, 94, 95, 96, 97, 98, 99, 100] . In these studies, CS has shown to be safe and, generally, exhibited slight to moderate efficacy over placebo in pain relief and function improvement in osteoarthritis patients. Also, CS is included in eye drop solutions for dry eyes [79, 80] . Preservative-free ophthalmic solutions combining xanthan gum and CS or combining sodium HA and CS showed similar efficacy compared to polyethylene glycol and propylene glycol solutions in the treatment of dry eye disease. The CS oral supplementation in combination with glucosamine hydrochloride has also shown improved therapeutic benefits in reducing systemic inflammation in overweighted individuals, over placebo [101] . For interstitial cystitis, the intravesical treatment with CS achieved improved efficiency in pain reduction and nocturia and had superior tolerability over DMSO, a standard approved therapy [84] . CS is also found in solutions for preserving corneas [102] , or in injectable devices to protect the eye during cataract surgery (phacoemulsification) [82, 83] . The ophthalmic viscosurgical devices containing HA and CS (DisCoVisc, Viscoat and Duovisc) showed greater efficiency during phacoemulsification, and improved protection of corneal endothelium, compared to hydroxypropylmethylcellulose [82] and to HA and lidocaine hydrochloride (Visthesia) injectables [83] . In addition, the potential applications of exogenous CS are wideranging since CS exhibits anti-inflammatory activity [50, 103, 104, 105, 106] , anticoagulant properties [53, 54, 107] , promotes the regeneration of different tissues [108, 109, 110] , has antiviral activity [111 -116] , and can be used in cancer treatment [47, 105] . Specifically, CS-E has been considered a powerful antiviral agent against flavivirus dengue, herpes viruses and T-cell leukemia virus type I [111, 112, 114] , tobacco mosaic virus is inhibited by CS-A and CS-C [113] , fCS showed inhibitory activity against human immunodeficiency virus type-1 [115] and against severe acute respiratory syndrome coronavirus 2 (SAR-S-CoV-2) [116] . CS has also potential applications in engineering scaffolds for regenerative medicine and tissue engineering, by combination with other biopolymers such as HA and collagen [117, 118] . DS exhibits several reported therapeutic applications. Drug formulations of DS have been marketed for the prevention of venous thromboembolism under the commercial names Mistral (Mediolanum Farmaceutici, Milan, Italy) [119] and Venorix (Laboratório Medinfar, Amadora, Portugal). It is also a component of sulodexide, a more widely-used antithrombotic agent [120] . Table 2 lists clinical trials with recently published results where CS or DS are used as treatment for different conditions, either as single GAG in the formulation or when formulated with other GAGs. Enzymes can be used to produce CS oligosaccharides by degrading CS polymers or by synthesizing CS oligosaccharides/polymers through polymerization. The main advantages of using enzymes over chemical approaches is that enzymes catalyze stereoselective and regioselective reactions, potentially resulting in homogeneous CS in an eco-friendlier and faster manner [136, 137] . However, these enzymatic steps are often combined with chemical synthesis or modifications (chemoenzymatic strategies) to either provide synthetic precursors or to perform the sulfation step. The depolymerizing/ degrading enzymes and the polysaccharide substrates used are relatively inexpensive [136] . However, the commercial polysaccharides are usually from animal sources which raises the concerns already mentioned. The degrading enzymes will be briefly discussed since they can give insights on structural analysis of CS, and because they can perform the contrary polymerization reaction under certain conditions. Enzymatic synthesis of CS from natural and unnatural precursors is the alternative for the preparation of homogeneous CS that most resembles the biological process. However, the high cost of such precursors generally limits the industrial implementation of these enzymatic methods. CS depolymerizing enzymes able to produce CS oligosaccharides are CS lyases [138, 139, 140] and CS hydrolases [141] . While polysaccharide hydrolases are found in almost every organism, polysaccharide lyases do not occur in vertebrates. According to their substrate specificity, the polysaccharide lyases acting on CS can be classified into chondroitinases ABC, AC, B, and C. They perform the depolymerization of CS/DS polymers via endolytic or exolytic β-elimination resulting mainly in unsaturated oligosaccharides [138, 140] . [135] of different CS lyase producers [138, 140, 142, 143] . Differently from CS lyases, CS hydrolases usually depolymerize CS with no unsaturated bonds formed, which make them more attractive for the enzymatic production of CS [1] . Some animal HA hydrolases, hyaluronidases, show depolymerizing activity against CS and some isoforms can only accept CS as substrate [144, 145] . Therefore, these hyaluronidases have been used to depolymerize CS polysaccharides to obtain CS oligosaccharides ( Fig. 2a) up to tetrasaccharides. The substrate specificity of CS lyases and CS hydrolases can retrieve functional characterization of GAGs. For synthesis of CS oligosaccharides and polysaccharides, degrading enzymes that in the reverse direction synthesize polymers (such as hyaluronidases, Fig. 2b ), or synthases (such as glycosyltransferases, Chemoenzymatic methods using HA or CS degrading enzymes in the anabolic direction for the production of CS and its derivatives have been established, by either ring-opening polyaddition [146, 147] or by transglycosylation reaction [148] . The works of Kobayashi et al. [146] and Fujikawa et al. [147] used testicular hyaluronidases from ovine or bovine to catalyze the synthesis of structurally defined CS (natural and unnatural) from chemically synthesized disaccharide oxazoline precursors which acted as transition state analogues. Kakizaki et al. [148] used immobilized bovine testicular hyaluronidase to produce hybrid polysaccharides composed by both HA and CS units. First, the hyaluronidase was used to prepare oligosaccharides by digestion of commercial CS and HA polysaccharides. The oligosaccharides were fluorolabeled (to facilitate analytical identification) generating pyridylaminated acceptors which underwent transglycosylation catalyzed by immobilized hyaluronidase using HA and CS donor polysaccharides. These methods enabled to control the molecular weight of the resulting CS and the construction of unnatural CS derivatives. However, the use of expensive sugar precursors and dedicated reactors, as well as the low product yields are drawbacks that limited large-scale application [149] . The discovery of microbial counterparts of glycosyltransferases in pathogenic bacteria further boosted the development of enzymatic strategies to produce chondroitin and CS. Bacterial glycosyltransferases used for chondroitin synthesis, also named chondroitin synthases or chondroitin polymerases, include PmCS from Pasteurella multocida and KfoC from E. coli K4 strains. These enzymes act by transferring alternate residues of GlcA and GalNAc, using uridine diphosphate (UDP)-GlcA and UDP-GalNAc as donors, to the nonreducing end of a chondroitin chain acceptor to form chondroitin oligosaccharide backbones (Fig. 2c) . DeAngelis et al. [150] identified for the first time a microbial gene encoding the chondroitin synthase PmCS and cloned it in E. coli. The same authors further used this recombinant glycosyltransferase for in vitro production of chondroitin from the substrates UDP-GlcA and UDP-GalNAc [151] . Other microbial glycosyltransferase KfoC was used by Sugiura et al. [152] to produce chondroitin oligosaccharides (CS-O) with controlled size from 7-mer to 16-mer. The authors first digested a commercial unsulfated chondroitin polymer with hyaluronidase to achieve even-numbered oligosaccharides. Further digestion with β-glucuronidase allowed to obtain odd-numbered oligosaccharides. The oligosaccharides were subjected to pyridylamination to facilitate their analysis. Then, two mutated recombinant KfoC enzymes were expressed each being selective for one of the substrates (UDP-GlcA or UDP-GalNAc) and the engineered enzymes, immobilized in beads, were used to elongate the chondroitin chain. The same group employed chemoenzymatic strategies for the preparation of CS oligosaccharides and polysaccharides with different sulfation patterns using the CS polymerase KfoC and recombinant sulfotransferases C4OST, C6OST, GalNAc4S-6OST and 2OST [153, 154, 155] . The chondroitin backbone was obtained by desulfating commercial CS from different sources and HEK293T cells were used to express the human sulfotransferases. However, the resulting products were heterogeneous, low amounts were achieved, and the process required laborious techniques for the separation of oligosaccharides with different sizes. Afterwards, the enzymatic production of 15 structurally diversified and homogeneous CS-A and CS-C oligosaccharides was achieved using KfoC expressed in E. coli BL21 [156] . Amounts of 4 -30 mg of CS oligosaccharides were obtained. The authors also synthesized the expensive substrate UDP-GalNAc using Bifidobacterium longum N-acetylhexosamine kinase and human GalNAc pyrophosphorylase both expressed in E. coli BL21, which significantly reduced the process cost. Human C4OST and mouse C6OST were afterwards used for sulfation of chondroitin backbones. Sf9 insect cells were used to express C4OST and C6OST. The authors were unsuccessful expressing C6OST in E. coli which they rationalized to be due to the glycosylation being required for the sulfotransferase activity as shown in Yusa et al. [157] . Accordingly, attempts to express soluble mouse C4OST in E. coli were also unsuccessful, and C4OST and C6OST were effectively expressed and secreted by the Pichia pastoris [158] . However, active human C4OST has been expressed in E. coli BL21 and P. pastoris [159] . Those authors showed that the glycosylated and non-glycosylated forms of the enzyme had similar activities. More recently, the soluble expression of human C4OST enzyme was also achieved in E. coli K4 and in E. coli K-12 MG1655 [160] . In addition to the most common CS types, CS-A and CS-C, efforts to enzymatically produce alternative CS structures have resulted in the synthesis of CS-E. Despite the enzymatic synthesis of structurally heterogeneous CS-E polysaccharides has been primarily reported [161] , the enzymatic production of homogenous CS-E oligosaccharides was more recently achieved [106] . The process included a serial elongation of p-nitrophenyl glucuronide (GlcA-pNP) with UDP-GalNAc using KfoC followed by the sulfotransferase modifications on the unsulfated backbone by C4OST and GalNAc4S-6OST. Mouse GalNAc4S-6OST was expressed in Sf9 cells, the glycotransferase KfoC and C4OST were expressed as in Li et al. [156] and the structural units UDP-GlcA, UDP-GalNAc, and the co-factor PAPS were synthesized by enzymatic approaches. Another recently reported chemoenzymatic strategy for the synthesis of homogenous chondroitin polymers combined stepwise oligosaccharides synthesis from GalNAc and GlcA units with further enzymatic polymerization by PmCS [162] . The authors showed that PmCS needs a suitable oligosaccharide (at least a chondroitin trisaccharide) as the acceptor to trigger the in vitro chondroitin chain polymerization. The polymers were further chemically sulfated to form CS. Even when the CS backbone is not obtained through enzymatic polymerization, enzymatic in vitro reactions can be used to participate in the post-polymerization modification of the chondroitin backbone. Rat aryl sulfotransferase IV (ASST IV) expressed in E. coli and mouse C4OST and C6OST sulfotransferases expressed in P. pastoris were used to modify a chondroitin backbone produced in vivo [158] . Instead of using sulfotransferases to add sulfate groups to the chondroitin, an alternative way to produce structurally defined CS was performed by employing a chemoenzymatic strategy for regioselective desulfation using a recombinant 4-O-endo-sulfatase from B. thetaiotaomicron [163] . Regarding the sulfate donor for sulfotransferases, PAPS, a chemoenzymatic synthesis [164] , enzymatic [165] or in vivo production using engineered E. coli [166] are recent attractable strategies to supply this co-factor for the synthesis of CS. These strategies have been applied for CS-A synthesis in vitro [166] and in vivo [160] . Drawbacks of the enzymatic CS synthesis include difficulty in controlling glycosyltransferase and sulfotransferase activities for a homogenous compound with a defined sulfation pattern [136] . The chemoenzymatic CS synthesis can provide the flexibility of chemical synthesis along with the efficiency and selectivity offered by enzymes to produce more defined CS oligosaccharides [167] . Nevertheless, the poor availability of substrates and co-factors, the poor enzymes activity and consequent low CS yields are still major limitations for the implementation of enzymatic and chemoenzymatic methods at industrial scale [168] . Biotechnological processes using microorganisms have been developed for the production of GAGs and its oligosaccharides, based on the ability of certain pathogenic microbes to produce them. This strategy offers several advantages over animal extraction or chemical synthesis, such as avoiding using expensive substrates and environment-hazard chemicals, avoiding interspecies infection or contaminations, improving homogeneity, and precisely controlling the degree of sulfation and molecular weight [1] . The main benefit of producing GAGs in vivo over the enzymatic methods is taking advantage of biological machinery to avoid the use of expensive substrates and co-factors (and instead use cheap simple carbon sources as substrates). However, the industrial biotechnological production of GAGs, and specially of sulfated GAGs such as CS, is limited due to safety concerns for culturing pathogenic microorganisms and low yields [169] . Therefore, research efforts have been focused on the improvement of the production process, as well as on the design of better microbial cell factories for production of GAGs. An overview on the metabolic pathways from native microbial GAG producers will be provided, which can give insights on the design of biosynthetic pathways for chondroitin and CS production. Then it is discussed the current state of the biotechnological production of chondroitin and CS. In Table 3 , advantages and disadvantages of the available chondroitin production methods are summarized. As already mentioned, native microbial GAG and GAG-like producers are pathogens that use these compounds as constituents of their capsule to camouflage their infection and improve pathogenicity [6] . In these microorganisms, the genes involved in the capsular polysaccharide production from UDP-sugars and its transport are usually expressed in the form of an operon. The pathways for the biosynthesis of microbial GAGs are represented in Fig. 3 . Representative native GAG-producers are E. coli K4 for chondroitin, E. coli K5 for heparosan, and P. multocida type A for HA. Capsular polysaccharide synthesis gene cluster includes three functional regions. Region 1 and region 3 are mainly responsible for the modification, transport, and localization of newly synthesized polysaccharide chain. Region 2 is mostly responsible for encoding enzymes related to the synthesis of polysaccharides and their precursors, so it is the most variable region across strains, according to the capsular GAG produced. The polymerization of these capsular polysaccharides occurs entirely on the cytoplasm through the action of glycosyltransferases followed by transportation, known to be adenosine triphosphate (ATP)-binding cassette (ABC) transporterdependent [4, 170, 171, 172] . Organisms producing other GAGs may comprise an important source of genes with relevance for the chondroitin heterologous pathway given that the majority of the steps involved in such production are the same. HA is naturally produced by Streptococcus group A or C and by P. multocida type A [6, 172, 173, 174, 175, 176] . The genes required for HA biosynthesis are encoded by the HA synthesis (HAS) operon (hasA-E) in Streptococci. Since HA does not require modifications after polymerization, the product from the fermentation can be directly isolated and purified. Commercial HA has been obtained mainly by microbial fermentation of Streptococcus equi and S. zooepidermidis [176, 177] . Industrial production of sulfated GAGs is more challenging because it requires post-polymerization modifications of the microbially-produced polysaccharide backbone. Biosynthesis of HP from microbial sources requires the microbial production of the precursor heparosan [178, 179, 180] with further chemical and/or enzymatic modifications [19, 181, 182, 183, 184] . E. coli K5, P. multocida type D and Avibacterium paragallinarum genotype II can synthesize heparosan [35, 36, 185, 186] . High titers of heparosan have been achieved using E. coli K5 (up to 15 g/L in bioreactor) [178, 179] which has the heparosan biosynthetic genes encoding glycosyltransferases and dehydrogenases organized in an operon (kfiA-D, Fig. 3) . Regarding DS and KS, there have been no reports on their production using microorganisms. Unsulfated chondroitin, a starting material for CS, is produced by P. multocida type F and A. paragallinarium genotype I [35, 36] . The pathogenic strain E. coli K4 natively synthesizes a capsular polysaccharide that shares a similar structure with the unsulfated chondroitin, but contains a residue of fructose [187] . Table 4 presents recent reported studies on in vivo production of chondroitin and CS, including in native producers and in heterologous hosts. E. coli K4 became the first and most studied microorganism to be used for the biotechnological production of chondroitin [37] . In fact, food grade CS has been industrially produced by microbial fermentation. The native producer E. coli K4 is used to produce microbial K4 polysaccharide followed by its chemical defructosylation and regioselective sulfation into CS sodium. The product is sold under the name of Mythocondro™ (marketed since 2017 by Gnosis S.p.A., which was acquired by Lesaffre in 2018). The genes required for fructosylated chondroitin production and transportation in E. coli K4 are organized in an operon containing kfoA-G genes. From the seven constituent genes, the most relevant genes in the biosynthesis of fructosylated chondroitin are: kfoA encoding UDP-GlcNAc 4-epimerase that provides UDP-GalNAc; kfoC encoding chondroitin synthase (homolog to PmCS); and kfoF encoding UDP-glucose dehydrogenase that provides UDP-GlcA. Fructosylated chondroitin can undergo a subsequent step of hydrolysis of fructose monomer and chemical sulfation [188, 189, 190] . The identification of the enzyme responsible for inserting the fructose residue (KfoE, fructosyltransferase) and its consequent deletion led to the production of unsulfated chondroitin [191] . Genetic engineering has been applied to E. coli K4 to further improve the polysaccharide yields [61, 63, 187, 190, 192, 193, 194, 195] . In fact, the highest reported yields so far for biotechnological production of chondroitin have been achieved with genetically engineered E. coli K4 through fed-batch fermentations, reaching 8.43 -9.2 g/L of fructosylated chondroitin [187, 192] . Feeding alternative synthetic precursors to the fermentation medium is a possible strategy to synthesize rare or unnatural chondroitin derivatives in vivo. In the work of Awofiranye et al. [196] , N-glycolyl chondroitin has been produced from chemically synthesized precursors (N-glycolylglucosamine replacing GlcNAc in the pathway) in E. coli K4 lacking kfoE gene. The first study aiming to produce chondroitin in a heterologous host used the pathogenic bacteria E. coli K5 expressing kfoC and kfoA from E. coli K4 and 52.6 mg/L of chondroitin was produced without the need for defructosylation [197] . Other pathogen, HA producer S. zooepidemicus, was also attempted as an heterologous host for chondroitin using the same genes [176] but it also resulted in low yields (300 mg/L). To avoid the contamination of the final product with virulence factors and toxins and to eliminate the defructosylation step, alternative microorganisms have been engineered with K4 polysaccharide production pathway. The chondroitin production in non-pathogenic heterologous hosts has been achieved in E. coli BL21 (DE3) [198] , B. subtilis [158, 180, 199] , Corynebacterium glutamicum [200] and E. coli K-12 [160, 201] . Using safer heterologous hosts, the highest chondroitin yield reported (2.4 g/L) was achieved by expressing kfoC, kfoA, kfoF in E. coli BL21 using the high copy number vector pETM6, with a pseudo-operon gene configuration [198] . The chondroitin backbone can be further modified through the action of various sulfotransferases to produce CS, or it can undergo epimerization of GlcA into IdoA and subsequent sulfation to generate DS. Several studies combined the microbial in vivo production of chondroitin with enzymatic or chemical strategies to produce CS [158, 166, 202] . By combining the in vivo production of chondroitin backbone and in vitro enzymatic sulfation, CS-A and CS-C production has been achieved [158] . Bacillus subtilis harboring the kfoA and kfoC genes from E. coli K4 was engineered. E. coli was used to express rat aryl sulfotransferase IV (ASST IV) and P. pastoris was the expression host for mouse C4OST and C6OST sulfotransferases. In the work of Erenler [202] , a non-pathogenic E. coli strain was engineered to express a previously described biosynthetic pathway for chondroitin production [198] along with a Vitreoscilla hemoglobin gene (vgb) whose expression has previously been reported to provide benefits to bacteria growth and recombinant protein expression and improved accumulation of different biopolymers [203] . The authors produced and purified the microbial chondroitin and performed chemical sulfation. Recently, the construction of the complete pathway for in vivo production of sulfated chondroitin in E. coli has been reported [160] . The authors evaluated both E. coli K4 and K-12 (containing K4 kfoCAF chondroitin genes) with expression of C4OST and PAPS reductase (cysH) deletion (to improve the pool of sulfate donor PAPS) for CS production. Only E. coli K4 was able to produce extracellular CS (10.76 µg/L in shaken flasks), and the intracellular yield was also higher than the one found for the engineered E. coli K-12. However, the percentage of sulfation of intracellular CS was 36% higher in the K-12 strain. After improving the activity of C4OST through mutation, optimizing growth and C4OST induction conditions, and inhibiting transport system through clustered regularly interspaced short palindromic repeats interference (CRISPRi), the levels of sulfation (~55%) reached the same ones achieved in K-12. The authors also optimized the fermentation process in bioreactor using K-12 which resulted in 27 μg/g dry cell weight of intracellular CS-A with a sulfation degree of 96%, a level of 4-O-sulfation similar to the ones found in animals. More recently, P. pastoris has been successfully engineered towards the production of CS-A using methanol as substrate [204] . The expression of kfoC and kfoA from E. coli K4, tuaD from B. subtilis, engineered mouse C4OST and overexpression of endogenous genes coding adenosine-5 ′ -triphosphate sulfurylase (ATPS) and adenosine-5 ′ -phosphosulfate kinase (APSK) to improve PAPS supply and sulfation, resulted in a production of 2.1 g/L CS-A with 4.0% sulfation using a fed-batch fermentation. The integrated approach from these two recent studies [160, 204] provides significant cost reduction to the process. However, the CS yields in E. coli are still low while the CS produced by engineered P. pastoris has a low sulfation degree. Therefore, more efforts are required to genetically improve the host and to optimize the process towards interesting yields and sulfation degrees for biotechnological applications. Despite the recent advances on biotechnological production of CS, the yields are still not sufficient to meet the increasing demand of this widely used nutraceutical. Metabolic engineering of the host microorganisms for improving CS precursors (UDP-GlcA, UDP-GlcNAc and UDP-GalNAc) production pathways should be performed to improve intermediate pools and their subsequent availability. In order to redirect the metabolic flux towards chondroitin or CS production in microbes, the most obvious modification is the overexpression of chondroitin polymerase/synthase which in E. coli K4 is encoded by kfoC. When kfoC was overexpressed in E. coli K4 using plasmids, the fructosylated chondroitin yield improved 2-fold compared to the wild-type [61] . When the kfoC overexpression was IS2 transposon-mediated, the K4 production was 2.5 times higher than the wild-type [205] . Strategies to improve KfoC enzymatic activity have also been addressed. By using random mutagenesis it was possible to improve KfoC activity (R313Q) that led to 82% improvement on fructosylated chondroitin over the wild-type [207] . Regulatory elements of expression of the bacterial GAG-like polysaccharides have also been targets for genetic engineering. The overexpression of the transcriptional activators rfaH [63] and slyA [194] have enhanced the expression of capsular genes and consequently improved E. coli K4 polysaccharide production by 58% and by a 1.5-fold, respectively, over the wild-type. RfaH acts on capsular gene cluster by preventing the transcript termination of genes related to the modification, transport, and localization of newly synthesized polysaccharide chain (region 3 genes), and consequently improve the expression of genes related to the synthesis of polysaccharides and their precursors (region 2 genes) [208] . SlyA activates the transcription of the whole capsular gene operon [194] . Regarding the precursor availability, balancing UDP-sugars is an established strategy for metabolic engineering of HA [209] and fructosylated chondroitin [187] . The genes pgm, galU and ugd/kfoF (encoding phosphoglucomutase, uridine triphosphate-glucose-1-phosphate uridylyltransferase and UDP-glucose dehydrogenase, respectively) for UDP-GlcA synthesis and glmS, glmM and glmU (encoding glucosamine-6phosphate synthase, phosphoglucosamine mutase and glucosamine-1phosphate N-acetyltransferase/N-acetylglucosamine-1-phosphate uridyltransferase, respectively) for UDP-GalNAc production might be interesting targets for overexpression (Fig. 3) . Overexpression of these genes have resulted in improved production of K4 and other polysaccharides. Levander and coworkers [210] found that the overexpression of the endogenous galU gene in S. thermophilus LY03 led to a 10-fold increase in galU activity, however exopolysaccharide yield was not affected. Nevertheless, when galU was overexpressed in combination with pgmA (pgm homolog), the exopolysaccharide yield increased. Overexpression of pgm and galU in E. coli AD202 also resulted in increased UDP-galactose derived disaccharides from 2.5 mM to 20 mM by improvement of carbon flux through UDP-glucose synthesis pathway [211] . Engineering E. coli K4 with one copy of endogenous genes pgm and galU also improved capsular polysaccharide production [65] . The authors further increased capsular polysaccharide yields in 45% using glutamine supplementation to boost UDP-GalNAc precursor production [63, 65] . Engineering Saccharomyces cerevisiae with the endogenous genes pgm2 and ugp1 (equivalent to galU) resulted in a 17% improvement of scutellarein 7-O-glucoside production rate by improving UDP-glucose pool [212] . Overexpressing glmM and glmU genes resulted in higher capsular polysaccharide production in E. coli K4 [206] . Despite the step catalyzed by ugd-codified enzyme was considered in previous works as the limiting factor of GAG biosynthesis in homologous and heterologous organisms [61, 180, 213, 214] , few examples evaluating alternative genes for this step have been reported, possibly missing interesting catalysts. On the other hand, the repression of genes from competing pathways can also be beneficial for redirecting the metabolic flux towards the production of GAG precursors. Down-regulating the expression of three genes (glucose-6-phosphate 1-dehydrogenase zwf, adenosine triphosphate-dependent 6-phosphofructokinase pfkA, and glmM) that control the major competing reactions (cell wall recycling pathways) of GlcNAc synthesis by CRISPRi improved GlcNAc titers in B. subtilis [215] . Silencing zwf and pfkA also resulted in improved HA production in B. subtilis [216] . By favoring the production of fructose 6-phosphate, pfkA knock-out resulted in increased chondroitin production in E. coli K4 [187] . Combination of both repression and activation can provide optimized microbial cell flux towards GAGs production. Knock-out of pfkA and zwf genes coupled with overexpression of the genes galU-ugd and glmS-glmM-glmU improved HA production [217] in E. coli K-12 W3110 harboring HA synthase gene (hasA) from S. zooepidemicus, and with transcriptional repressors genes galR and galS deleted. When the intended biosynthetic pathway has intermediates that are critical for biomass production, as it is the case for chondroitin, redirecting the carbon flux might result in lower yield and growth rate. To assess this question, there have been interesting advances on dynamical control to balance the metabolic flux according to the intermediate concentration. This strategy has been applied for overproduction of GlcNAc in B. subtilis which consisted in engineering the native glucosamine-6-phosphate responsive glmS ribozyme switch to act as a sensor and dynamically control the metabolic flux [218] . This strategy increased about 2-fold the native GlcNAc titer, being a potential strategy to improve chondroitin producing strains. Finally, computational methods can be useful to aid on the prediction of potential targets for improving CS production in heterologous hosts. The use of stoichiometric or kinetic models of the heterologous host to perform in silico predictions has been shown to be useful to guide engineering strategies towards the improved production of valuable compounds. In fact, a computational approach was already performed to engineer an optimal HA production in C. glutamicum [219] . Sophisticated genetic engineering tools for genome editing, such as CRISPR [220] , are shown to be rapid and cost-effective and, therefore, can be implemented on the intended system to generate engineered hosts with improved chondroitin production. Alternative hosts can provide more suitable platforms for CS production. Besides replacing the native pathogenic bacteria and, consequently, avoiding the presence of virulence factors in the final product, the application of industrially used E. coli, B. subtilis, and Corynebacterium for CS production has the advantages of being fast-growing organisms, with well-characterized genetic and physiological backgrounds, and many available tools for gene expression and genome editing [221] . However, biosynthetic enzymes expressed in bacterial systems usually present low solubility, stability, and activity, which may limit CS synthesis. On the other hand, enzymes expressed in eukaryotes typically show enhanced activity but are expressed at lower amounts [167] . Specially for the expression of eukaryotic genes, in particular sulfotransferases, eukaryotic microbial cells such as the broadly used S. cerevisiae and P. pastoris can provide beneficial conditions regarding codon preference, enzyme folding and glycosylation patterns more similar to the original enzymes. Also, since mammalian CHO cells have shown to be able to produce HP [222] , animal cell fermentation can also be a possible, however expensive, alternative strategy for the production of CS. Besides the metabolic engineering strategies to improve intermediate pools, or the use of alternative hosts, other approaches to make biotechnological CS production more cost-effective include screening for more efficient enzymes, modification of the enzymes through protein engineering and immobilization to improve activity and productivity. Also, salvage pathways can be added to improve precursorsfor example, UDP-GlcA can also be produced in two different ways directly from GlcA using glucuronokinase, UDP-sugar pyrophosphorylase, and inorganic phosphatase instead of depending on UDP-glucose conversion through ugd step. Increasing energy through ATP supply, and implementing ATP regeneration systems can also benefit the CS in vivo production. The control of CS molecular weight in fermentation is also desirable to achieve a more monodisperse product [190, 223] . In addition, optimization of the fermentation process, media composition, temperature and pH conditions have been shown to be effective for improved GAG yields [178, 224] . Using low-cost media can provide a more competitive process, namely agro-industrial by-products such as sugarcane molasses and corn steep liquor which have already been used for HA production [225, 226, 227] , therefore they present potential applicability for CS production. Additionally, engineering of CS transportation can aid to improve CS titers, by even repressing transporters for increased CS intracellular in vivo sulfation [160] , or by contrarily strengthening cell CS exportation, which would be more valuable from an industrial point of view but would require the extracellular expression of the sulfotransferases. Finally, optimizing environmental conditions for maximal enzyme activity to perform the post-polymerization modifications of biotechnological CS polysaccharides in vivo or in vitro would aid to obtain a final commercial sulfated product at competitive yields. Compared to animal-derived products, heterologous microbes can provide pathogen-free chondroitin without the use of hazardous chemicals. With the increasing applications of CS, the studies on its microbial production have been growing with much focus on the native GAG producers' pathway to polymerize the backbone starting material, and on its post-polymerization modifications through enzymatic in vitro reactions. However, there are bottlenecks such as insufficient supply of precursors, low activity and/or stability of the enzymes and difficult and costly sulfotransferase enzymes purification. Strategies that can help solving these issues include genetic engineering for improving the precursors pool and transport; evaluation of alternative hosts for efficient expression of enzymes (since most genes required for sulfated GAGs production are from animals, expression in eukaryotic hosts could provide more soluble and active enzymes); improvement of enzyme activity and solubility through enzyme engineering and environment optimization; and the use of integrated approaches of microbial production and post-polymerization. The knowledge improvement on GAGs enzymes for polymerization, transport and post-polymerization, together with the development of efficient technologies for gene editing, are expected to lead to the establishment of efficient microbial cell factories for the CS production. The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper. Bio-based strategies for producing glycosaminoglycans and their oligosaccharides Chemical synthesis of glycosaminoglycans Biochemistry, Glycosaminoglycans, StatPearls Publishing, Treasure Island (FL), 2021 Essentials of Glycobiology, Cold Spring Harb Applications of glycosaminoglycans in the medical, veterinary, pharmaceutical, and cosmetic fields Masquerading microbial pathogens: capsular polysaccharides mimic host-tissue molecules UDP-glucose dehydrogenase gene of Xanthomonas campestris is required for virulence Molecular pathogenesis of the hyaluronic acid capsule of Pasteurella multocida Medical application of glycosaminoglycans: a review Therapeutic Applications of glycosaminoglycans Handbook of Glycomics Hyaluronic acid and chondroitin sulfate from marine and terrestrial sources: extraction and purification methods Microbial production and metabolic engineering of chondroitin and chondroitin sulfate Microbial production of oligosaccharides and polysaccharides Galactosaminoglycans: medical applications and drawbacks Deciphering structural determinants in chondroitin sulfate binding to FGF-2: paving the way to enhanced predictability of their biological functions Recent advances in the structural study of functional chondroitin sulfate and dermatan sulfate in health and disease Development of semisynthetic, regioselective pathways for accessing the missing sulfation patterns of chondroitin sulfate Industrial production of glycosaminoglycans Functions of chondroitin sulfate and heparan sulfate in the developing brain Chondroitin sulfate: a key molecule in the brain matrix Biosynthesis and function of chondroitin sulfate Plasmodium falciparum ookinetes require mosquito midgut chondroitin sulfate proteoglycans for cell invasion Insight into the role of chondroitin sulfate E in angiogenesis Dermatan sulfate: new functions from an old glycosaminoglycan Isolation of dermatan sulfate proteoglycans from mature bovine articular cartilages Recent advances in the structural biology of chondroitin sulfate and dermatan sulfate Modulation of inflammation by chondroitin sulfate Recombinant dermatan sulfate is a potent activator of heparin cofactor II-dependent inhibition of thrombin Dermatan sulfate is the predominant antithrombotic glycosaminoglycan in vessel walls: implications for a possible physiological function of heparin cofactor II Identification and functions of chondroitin sulfate in the milieu of neural stem cells Marine polysaccharides for drug delivery in tissue engineering Molecular basis for the susceptibility of fibrin-bound thrombin to inactivation by heparin cofactor II in the presence of dermatan sulfate but not heparin Identification of the capsular polysaccharides of Type D and F Pasteurella multocida as unmodified heparin and chondroitin, respectively Analysis of the biosynthesis genes and chemical components of the capsule of Avibacterium paragallinarum Production of capsular polysaccharide from Escherichia coli K4 for biotechnological applications Structural analysis of chondroitin sulfate from Scyliorhinus canicula: a useful source of this polysaccharide Structural studies on sulfated oligosaccharides derived from the carbohydrate-protein linkage region of chondroitin sulfate proteoglycans of whale cartilage Structural studies on sulfated oligosaccharides derived from the carbohydrate-protein linkage region of chondroitin 6-sulfate proteoglycans of shark cartilage. I. Six compounds containing 0 or 1 sulfate and/or phosphate residue Involvement of chondroitin 6-sulfation in temporal lobe epilepsy Protective effects of low molecular weight chondroitin sulfate on amyloid beta (Aβ)-induced damage in vitro and in vivo Characteristic hexasaccharide sequences in octasaccharides derived from shark cartilage chondroitin sulfate D with a neurite outgrowth promoting activity Isolation and characterization of developmentally regulated chondroitin sulfate and chondroitin/keratin sulfate proteoglycans of brain identified with monoclonal antibodies Chondroitin sulfate/dermatan sulfate-protein interactions and their biological functions in human diseases: implications and analytical tools A novel chondroitin sulfate E from Dosidicus gigas cartilage and its antitumor metastatic activity Identification of chondroitin sulfate E proteoglycans and heparin proteoglycans in the secretory granules of human lung mast cells Two fucosylated chondroitin sulfates from the sea cucumber Eupentacta fraudatrix Structure and anti-inflammatory activity of a new unusual fucosylated chondroitin sulfate from Cucumaria djakonovi A highly regular fucosylated chondroitin sulfate from the sea cucumber Massinium magnum: structure and effects on coagulation The structure of a fucosylated chondroitin sulfate from the sea cucumber Cucumaria frondosa Purification, structural characterization and anticoagulant properties of fucosylated chondroitin sulfate isolated from Holothuria mexicana Comparison of structures and anticoagulant activities of fucosylated chondroitin sulfates from different sea cucumbers Structural determination of five novel tetrasaccharides containing 3-O-sulfated D-glucuronic acid and two rare oligosaccharides containing a β-D-glucose branch isolated from squid cartilage chondroitin sulfate E Structural determination of novel tetra-and hexasaccharide sequences isolated from chondroitin sulfate H (oversulfated dermatan sulfate) of hagfish notochord Functional chondroitin sulfate from Enteroctopus dofleini containing a 3-O-sulfo glucuronic acid residue Novel sulfated oligosaccharides containing 3-O-sulfated glucuronic acid from king crab cartilage chondroitin sulfate K: unexpected degradation by chondroitinase ABC A novel pentasaccharide sequence GlcA(3-sulfate)(β1-3)GalNAc(4-sulfate)(β1-4)(Fucα1-3)GlcA(β1-3)GalNAc(4-sulfate) in the oligosaccharides isolated from king crab cartilage chondroitin sulfate K and its differential susceptibility to chondroitinases and hyalurinidase Isolation and structural determination of novel sulfated hexasaccharides from squid cartilage chondroitin sulfate E that exhibits neuroregulatory activities Improved fructosylated chondroitin production by kfoC overexpression in E. coli K4 Application of a 22L scale membrane bioreactor and cross-flow ultrafiltration to obtain purified chondroitin Homologous overexpression of rfaH in E. coli K4 improves the production of chondroitin-like capsular polysaccharide KfoE encodes a fructosyltransferase involved in capsular polysaccharide biosynthesis in Escherichia coli K4 Engineering a branch of the UDP-precursor biosynthesis pathway enhances the production of capsular polysaccharide in Escherichia coli O5:K4:H4 A red meat-derived glycan promotes inflammation and cancer progression Analysis of chondroitin sulfate from different sources of cartilage by electrophoretically mediated microanalysis Determination of chondroitin sulfate from different sources of cartilage Established method of chondroitin sulphate extraction from buffalo (Bubalus bubalis) cartilages and its identification by FTIR Chicken keel cartilage as a source of chondroitin sulfate By-products of Scyliorhinus canicula, Prionace glauca and Raja clavata: a valuable source of predominantly 6S sulfated chondroitin sulfate Swine, Poultry), By Application (Nutraceuticals, Pharmaceuticals, Animal Feed, Personal Care & Cosmetics), and Segment Forecascts Chondroitin sulfate market intelligence. Price, forecast, cost models, market analysis -market research Glucosamine and chondroitin use in canines for osteoarthritis: a review, Open Vet Effect of an oral preparation containing hyaluronic acid, chondroitin sulfate, hydrolyzed collagen type II and hydrolyzed keratin on synovial fluid features and clinical indices in knee osteoarthritis. A pilot study Systematic analysis of pharmaceutical preparations of chondroitin sulfate combined with glucosamine Oral chondroprotection with nutraceuticals made of chondroitin sulphate plus glucosamine sulphate in osteoarthritis Clinical review of chondroitin sulfate in osteoarthritis Efficacy of a fixed combination of 0.09% xanthan gum/0.1% chondroitin sulfate preservative free vs polyethylene glycol/ propylene glycol in subjects with dry eye disease: a multicenter randomized controlled trial Efficacy and safety of sodium hyaluronate/ chondroitin sulfate preservative-free ophthalmic solution in the treatment of dry eye: a clinical trial Double blind, placebo controlled trial of a topical cream containing glucosamine sulfate, chondroitin sulfate, and camphor for osteoarthritis of the knee A clinical comparison between discovisc and 2% hydroxypropylmethylcellulose in phacoemulsification: a fellow eye study Cohesive versus dispersive-cohesive ophthalmic viscosurgical device in torsional intelligent phaco A prospective randomized controlled multicentre trial comparing intravesical DMSO and chondroïtin sulphate 2% for painful bladder syndrome/ interstitial cystitis Intravesical administration of combined hyaluronic acid (HA) and chondroitin sulfate (CS) for the treatment of female recurrent urinary tract infections: a European multicentre nested case-control study Recent advance in delivery system and tissue engineering applications of chondroitin sulfate Chondroitin sulphate for the treatment of osteoarthritis Effectiveness and safety of glucosamine and chondroitin for the treatment of osteoarthritis: a meta-analysis of randomized controlled trials Glucosamine and chondroitin for the treatment of osteoarthritis Effects of glucosamine, chondroitin, or placebo in patients with osteoarthritis of hip or knee: network meta-analysis Chondroitin for osteoarthritis update of the EULAR recommendations for the management of hand osteoarthritis Symptomatic effects of chondroitin 4 and chondroitin 6 sulfate on hand osteoarthritis: a randomized, double-blind, placebo-controlled clinical trial at a single center Effectiveness of chondroitin sulphate in patients with concomitant knee osteoarthritis and psoriasis: a randomized, double-blind, placebo-controlled study Chondroitin sulphate reduces both cartilage volume loss and bone marrow lesions in knee osteoarthritis patients starting as early as 6 months after initiation of therapy: a randomised, double-blind, placebocontrolled pilot study using MRI Levels of serum biomarkers from a two-year multicentre trial are associated with treatment response on knee osteoarthritis cartilage loss as assessed by magnetic resonance imaging: an exploratory study Chondroitin sulfate efficacy versus celecoxib on knee osteoarthritis structural changes using magnetic resonance imaging: a 2-year multicentre exploratory study Effect of chondroitin sulphate in symptomatic knee osteoarthritis: a multicentre, randomised, double-blind, placebo-controlled study Effect of 12 months treatment with chondroitin sulfate on cartilage volume in knee osteoarthritis patients: a randomized, double-blind, placebo-controlled pilot study using MRI Comparative efficacy and safety study of two chondroitin sulfate preparations from different origin (avian and bovine) in symptomatic osteoarthritis of the knee Randomized trial of glucosamine and chondroitin supplementation on inflammation and oxidative stress biomarkers and plasma proteomics profiles in healthy humans Randomized, prospective, single-masked clinical trial of endothelial keratoplasty performance with 2donor cornea 4 • C storage solutions and associated chambers Anti-inflammatory activity of chondroitin sulphate: new functions from an old natural macromolecule Anti-inflammatory activity of chondroitin sulfate Selectin blocking activity of a fucosylated chondroitin sulfate glycosaminoglycan from sea cucumber: effect on tumor metastasis and neutrophil recruitment Enzymatic synthesis of chondroitin sulfate E to attenuate bacteria lipopolysaccharideinduced organ damage Sulfation pattern of the fucose branch is important for the anticoagulant and antithrombotic activities of fucosylated chondroitin sulfates Chitosan, hyaluronan and chondroitin sulfate in tissue engineering for cartilage regeneration: a review Potential therapeutic application of chondroitin sulfate/ dermatan sulfate Chondroitin sulfate proteoglycans in neural development and regeneration Chondroitin sulfate characterized by the E-disaccharide unit is a potent inhibitor of herpes simplex virus infectivity and provides the virus binding sites on gro2C cells Antiviral activity of chondroitin sulphate E targeting dengue virus envelope protein Antiviral activity of chondroitin sulfate against infection Inhibitory effect of chondroitin sulfate type E on the binding step of human T-cell leukemia virus type 1 The depolymerized fucosylated chondroitin sulfate from sea cucumber potently inhibits HIV replication via interfering with virus entry Inhibitory activities of marine sulfated polysaccharides against SARS-CoV-2 Preparation of collagen-chondroitin sulfate-hyaluronic acid hybrid hydrogel scaffolds and cell compatibility in vitro Improving the moisturizing properties of collagen film by surface grafting of chondroitin sulfate for corneal tissue engineering Pharmacokinetics and pharmacodynamics of intramuscular dermatan sulfate revisited Development and use of sulodexide in vascular diseases: implications for treatment Multicenter, randomized, double-blind clinical trial to evaluate efficacy and safety of combined glucosamine sulfate and chondroitin sulfate capsules for treating knee osteoarthritis Combined chondroitin sulfate and glucosamine for painful knee osteoarthritis: a multicentre, randomised, double-blind, non-inferiority trial versus celecoxib Combined treatment with chondroitin sulfate and glucosamine sulfate shows no superiority over placebo for reduction of joint pain and functional impairment in patients with knee osteoarthritis: a six-month multicenter, randomized, double-blind, placebo-controlled clinical trial Treatment of knee osteoarthritis with a new formulation of a fixed-dose combination of glucosamine sulfate and bovine chondroitin: a multicenter, randomized, single-blind, non-inferiority clinical trial Effects of diet type and supplementation of glucosamine, chondroitin, and MSM on body composition, functional status, and markers of health in women with knee osteoarthritis initiating a resistancebased exercise and weight loss program Glucosamine and chondroitin for knee osteoarthritis: a double-blind randomised placebo-controlled clinical trial evaluating single and combination regimens Clinical risk factors associated with radiographic osteoarthritis progression among people with knee pain: a longitudinal study Prospective, multicenter, randomized, controlled trial evaluating the performance of a novel combination powder vs hemostatic matrix in cardiothoracic operations The effect of oral low molecular weight liquid hyaluronic acid combination with glucosamine and chondroitin on knee osteoarthritis patients with mild knee pain: an 8-week randomized double-blind placebo-controlled trial Efficacy and tolerability of progen, a nutritional supplement based on innovative plasma proteins, ACL reconstruction: a multicenter randomized controlled trial Efficacy of mesoglycan in pain control after excisional hemorrhoidectomy: a pilot comparative prospective multicenter study Design and rationale of a randomized, placebo-controlled trial on the efficacy and safety of sulodexide for extended treatment in elderly patients after a first venous thromboembolism Effect of sulodexide in patients with non-proliferative diabetic retinopathy: diabetic retinopathy sulodexide study (DRESS), Graefe's Arch Predictive properties of biomarkers GDF-15, NTproBNP, and hs-TnT for morbidity and mortality in patients with type 2 diabetes with nephropathy Sulodexide for kidney protection in type 2 diabetes patients with microalbuminuria: a randomized controlled trial Synthesis of structurally defined chondroitin sulfate: paving the way to the structure-activity relationship studies Chemoenzymatic synthesis of glycosaminoglycans: re-creating, re-modeling and re-designing nature's longest or most complex carbohydrate chains Chondroitin sulfate lyases: applications in analysis and glycobiology High-level production of ChSase ABC I by co-expressing molecular chaperones in Escherichia coli CS lyases: structure, activity, and applications in analysis and the treatment of diseases Chondroitin sulfate-specific novel hydrolase in human Purification, characterization of chondroitinase ABC from Sphingomonas paucimobilis and in vitro cardiocytoprotection of the enzymatically degraded CS-A A new member of family 8 polysaccharide lyase chondroitin AC lyase (PsPL8A) from Pedobacter saltans displays endo-and exo-lytic catalysis Hyaluronidase 1 and β-hexosaminidase have redundant functions in hyaluronan and chondroitin sulfate degradation Identification of amino acid residues required for the substrate specificity of human and mouse chondroitin sulfate hydrolase (Conventional hyaluronidase-4) Enzymatic synthesis of chondroitin and its derivatives catalyzed by hyaluronidase Enzymatic synthesis of chondroitin 4-sulfate with well-defined structure Hyaluronan-chondroitin hybrid oligosaccharides as new life science research tools Chondroitin sulfate: extraction, purification, microbial and chemical synthesis Identification and molecular cloning of a chondroitin synthase from Pasteurella multocida type F Chondroitin synthase gene and methods of making and using same Sequential synthesis of chondroitin oligosaccharides by immobilized chondroitin polymerase mutants Construction of a chondroitin sulfate library with defined structures and analysis of molecular interactions Molecular dissection of placental malaria protein VAR2CSA interaction with a chemo-enzymatically synthesized chondroitin sulfate library Sequence determination of synthesized chondroitin sulfate dodecasaccharides Enzymatic synthesis of homogeneous chondroitin sulfate oligosaccharides N-linked oligosaccharides on chondroitin 6-sulfotransferase-1 are required for production of the active enzyme, golgi localization, and sulfotransferase activity toward keratan sulfate A microbial-enzymatic strategy for producing chondroitin sulfate glycosaminoglycans Expression of chondroitin-4-O-sulfotransferase in Escherichia coli and Pichia pastoris Complete biosynthesis of a sulfated chondroitin in Escherichia coli Enzymatic synthesis of chondroitin sulfate E by N-acetylgalactosamine 4-sulfate 6-O-sulfotransferase purified from squid cartilage Chemoenzymatic synthesis of homogeneous chondroitin polymers and its derivatives A holistic approach to unravelling chondroitin sulfation: correlations between surface charge, structure and binding to growth factors Chemoenzymatic synthesis of 3 ′ -phosphoadenosine-5 ′ -phosphosulfate coupling with an ATP regeneration system Expression of enzymes for 3 ′ -phosphoadenosine-5 ′ -phosphosulfate (PAPS) biosynthesis and their preparation for PAPS synthesis and regeneration Increased 3 ′ -phosphoadenosine-5 ′ -phosphosulfate levels in engineered Escherichia coli cell lysate facilitate the in vitro synthesis of chondroitin sulfate A Chemoenzymatic synthesis of glycosaminoglycans Site-selective reactions for the synthesis of glycoconjugates in polysaccharide vaccine development Production of chondroitin sulfate and chondroitin Structure, biosynthesis, and function of bacterial capsular polysaccharides synthesized by ABC transporter-dependent pathways Assembly of bacterial capsular polysaccharides and exopolysaccharides Biosynthesis and regulation mechanisms of the Pasteurella multocida capsule Genetic basis for hyper production of hyaluronic acid in natural and engineered microorganisms Enhanced hyluronic acid production in Streptococcus zooepidemicus by over expressing HasA and molecular weight control with Niscin and glucose Characterization of UDP-glucose dehydrogenase from Pasteurella multocida CVCC 408 and its application in hyaluronic acid biosynthesis Engineering S. equi subsp. zooepidemicus towards concurrent production of hyaluronic acid and chondroitin biopolymers of biomedical interest Biotechnological production and application of hyaluronan E. coli K5 fermentation and the preparation of heparosan, a bioengineered heparin precursor Escherichia coli K5 heparosan fermentation and improvement by genetic engineering Efficient biosynthesis of polysaccharides chondroitin and heparosan by metabolically engineered Bacillus subtilis Response surface optimization of the heparosan N-deacetylation in producing bioengineered heparin Production methods for heparosan, a precursor of heparin and heparan sulfate Design of biologically active heparan sulfate and heparin using an enzyme-based approach Combinatorial one-pot chemoenzymatic synthesis of heparin New insight into chondroitin and heparosan-like capsular polysaccharide synthesis by profiling of the nucleotide sugar precursors Identification and characterization of a chondroitin synthase from Avibacterium paragallinarum Enhancing fructosylated chondroitin production in Escherichia coli K4 by balancing the UDP-precursors A microbiological-chemical strategy to produce chondroitin sulfate A, C, Angew. Chemie -Int Chondroitin sulfate, hyaluronic acid and chitin/chitosan production using marine waste sources: characteristics, applications and ecofriendly processes: a review Production and purification of higher molecular weight chondroitin by metabolically engineered Escherichia coli K4 strains Biotechnological production of chondroitin Biotechnological production of chondroitin Physiological characterization and quantitative proteomic analyses of metabolically engineered E. coli K4 strains with improved pathways for capsular polysaccharide biosynthesis Transcriptional engineering of Escherichia coli K4 for fructosylated chondroitin production Microbioreactor (micro-Matrix) potential in aerobic and anaerobic conditions with different industrially relevant microbial strains N-glycolyl chondroitin synthesis using metabolically engineered E. coli Chondroitin-producing bacterium and method of producing chondroitin Production of chondroitin in metabolically engineered E. coli Methods of expressing gram-negative glycosaminoglycan synthase genes in gram-positive hosts Biosynthesis of chondroitin in engineered Corynebacterium glutamicum Chemo-bacterial synthesis of conjugatable glycosaminoglycans Capsular polysaccharide biosynthesis from recombinant E. coli and chondroitin sülfate production Applications of the VHb gene vgb for improved microbial fermentation processes Biosynthesis of non-animal chondroitin sulfate from methanol using genetically engineered Pichia pastoris IS2-mediated overexpression of kfoC in E. coli K4 increases chondroitin-like capsular polysaccharide production Recombinant Escherichia coli for high efficiency production of fructosylated chondroitin and method for making thereof Isolation of an Escherichia coli K4 kfoC mutant over-producing capsular chondroitin Regulation of the Escherichia coli K5 capsule gene cluster by transcription antitermination Ratio of intracellular precursors concentration and their flux influences hyaluronic acid molecular weight in Streptococcus zooepidemicus and recombinant Lactococcus lactis Enhanced exopolysaccharide production by metabolic engineering of Streptococcus thermophilus Engineering the E. coli UDP-glucose synthesis pathway for oligosaccharide synthesis Engineering Saccharomyces cerevisiae with the deletion of endogenous glucosidases for the production of flavonoid glucosides Hyaluronic acid production in Bacillus subtilis Metabolic engineering of Escherichia coli for biosynthesis of hyaluronic acid CRISPRi allows optimal temporal control of N-acetylglucosamine bioproduction by a dynamic coordination of glucose and xylose metabolism in Bacillus subtilis Metabolic engineering to enhance heterologous production of hyaluronic acid in Bacillus subtilis Metabolic engineering of Escherichia coli for the production of hyaluronic acid from glucose and galactose Engineering a glucosamine-6-phosphate responsive glmS ribozyme switch enables dynamic control of metabolic flux in Bacillus subtilis for overproduction of Nacetylglucosamine Engineering Corynebacterium glutamicum for high-titer biosynthesis of hyaluronic acid CRISPR-Cas9: a powerful tool to efficiently engineer Saccharomyces cerevisiae Metabolic engineering of capsular polysaccharides Metabolic engineering of Chinese hamster ovary cells: towards a bioengineered heparin Molecular weight determination of heparosan-and chondroitin-like capsular polysaccharides: figuring out differences between wild -type and engineered Escherichia coli strains High cell density cultivation of Escherichia coli K4 in a microfiltration bioreactor: a step towards improvement of chondroitin precursor production Cheese whey: a cost-effective alternative for hyaluronic acid production by Streptococcus zooepidemicus Microbial production of hyaluronic acid from agro-industrial by-products: molasses and corn steep liquor Improvement production of hyaluronic acid by Streptococcus zooepidemicus in sugarcane molasses This study was supported by the Portuguese Foundation for Science and Technology (FCT) under the scope of the strategic funding of UIDB/ 04469/2020 unit. The authors acknowledge FCT for funding the doctoral grant SFRH/BD/132998/2017 to Couto, M. R.